Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations^*

References

• Russo MW, Wei JT, Thiny MT, et al. Digestive and liver diseases statistics, 2004. Gastroenterology 2004;126:1448–53
   PubMed Web of Science ®Google Scholar
• DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200
   PubMed Web of Science ®Google Scholar
• Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007;102:668–85
   PubMed Web of Science ®Google Scholar
• Ali MA, Lacy BE. Esophageal manometry and pH monitoring: gastroenterologists’ adherence to published guidelines. J Clin Gastroenterol 2005;39:584–90
   PubMed Web of Science ®Google Scholar
• Lowe RC, Wolf MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2004;50:227–37
   PubMedGoogle Scholar
• Pohland CJ, Scavnicky SA, Lasky SS, et al. Lansoprazole overutilization: methods for step-down therapy. Am J Manag Care 2003;9:353–8
   PubMed Web of Science ®Google Scholar
• Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000;18:20–6
   PubMed Web of Science ®Google Scholar
• Patti MG, Gorodner MV, Galvani C, et al. Spectrum of esophageal motility disorders: implications for diagnosis and treatment. Arch Surg 2005;140:442–8
   PubMed Web of Science ®Google Scholar
• Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243–5
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc 2004;292:1955–60
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 2006;296:2947–53
   PubMed Web of Science ®Google Scholar
• des Varannes SB, Mion F, Ducrotte P, et al. Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo). Gut 2005;54:1682–6
   PubMed Web of Science ®Google Scholar
• Pandolfino JE, Zhang Q, Schreiner MA, et al. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different? Gut 2005;54:1687–92
   PubMed Web of Science ®Google Scholar
• Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740–9
   PubMed Web of Science ®Google Scholar
• Wong WM, Bautista J, Dekel R, et al. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring – a randomized trial. Aliment Pharmacol Ther 2005;21:155–63
   PubMed Web of Science ®Google Scholar
• Lacy BE, O’Shana T, Hynes M, et al. Safety and tolerability of transoral bravo capsule placement after transnasal manometry using a validated conversion factor. Am J Gastroenterol 2007;102:24–32
   PubMed Web of Science ®Google Scholar
• Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2005;3:329–34
   PubMed Web of Science ®Google Scholar
• Hall J, Dodd S, Durkin M, et al. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care 2002;11:14–8
   PubMedGoogle Scholar
• Kaplan-Machlis B, Spiegler GE, Zodet MW, et al. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000;9:624–30
   Google Scholar
• Ofman JJ, Yamashita BD, Siddique RM, et al. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000;6:905–16
   PubMed Web of Science ®Google Scholar
• Sonnenberg A, Inadomi JM, Becker LA. Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1003–13
   Google Scholar
• Harewood GC, Gostout CJ. Cost analysis of endoscopic antireflux procedures: endoluminal application vs. radiofrequency coagulation vs. treatment with a proton pump inhibitor. Gastrointest Endosc 2003;58:493–9
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. Value Health 2007;10:336–47
   PubMed Web of Science ®Google Scholar
• van PB, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;19:3 [CD002095]
   Google Scholar
• Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999;231:3–8
   PubMedGoogle Scholar
• Anon. Redbook drug topics. Thomson Healthcare Inc.; 2006
   Google Scholar
• Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283–9
   Google Scholar
• Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;40:20–4
   Google Scholar
• Ahlawat SK, Novak DJ, Williams DC, et al. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system. J Clin Gastroenterol 2006;40: 20–4
   PubMed Web of Science ®Google Scholar
• Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol 2007;102:239–45
   PubMed Web of Science ®Google Scholar
• Anon. Pharmacy benefit report facts and figures. East Hanover (NJ): Novartis Pharmaceuticals; 2003
   Google Scholar
• Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006;101:2128–38
   PubMed Web of Science ®Google Scholar
• Cohen J, Safdi MA, Deal SE, et al. Quality indicators for esophagogastroduodenoscopy. Am J Gastroenterol 2006;101: 886–91
   PubMed Web of Science ®Google Scholar
• Sipkoff M. As drug payment model changes, confusion grows among insurers. Managed Care 2007;16(2):56–9
   Google Scholar
• Locke GR III, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29–34
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–79
   PubMed Web of Science ®Google Scholar